Could Biomarin Pharmaceutical Inc (NASDAQ:BMRN) Go Down After Its Newest Short Interest Report?

May 18, 2018 - By Donald McKee

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Investors sentiment increased to 1.21 in Q4 2017. Its up 0.08, from 1.13 in 2017Q3. It increased, as 37 investors sold BioMarin Pharmaceutical Inc. shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported.
Korea reported 1,595 shares or 0% of all its holdings. Howe And Rusling Incorporated reported 98 shares or 0% of all its holdings. Panagora Asset Mgmt has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). United Serv Automobile Association owns 38,390 shares for 0.01% of their portfolio. Oppenheimer Asset Mgmt holds 24,918 shares or 0.06% of its portfolio. Tokio Marine Asset Mgmt Ltd stated it has 0.38% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Comgest Global Sas invested 0.06% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Rafferty Asset Lc has invested 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Argent owns 6,210 shares or 0.22% of their US portfolio. Redmile Group stated it has 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Parametric Port Assocs Limited Liability Company holds 206,514 shares or 0.02% of its portfolio. Winslow Evans & Crocker, Massachusetts-based fund reported 78 shares. Caisse De Depot Et Placement Du Quebec invested in 0% or 2,800 shares. Greenwood Limited Com has invested 0.08% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Altrinsic Advsr Ltd Liability accumulated 56,168 shares or 0.19% of the stock.

Since December 14, 2017, it had 0 insider purchases, and 24 sales for $21.82 million activity. 15,000 shares were sold by BIENAIME JEAN JACQUES, worth $1.27 million on Thursday, March 15. Mueller Brian sold 2,450 shares worth $219,275. 1,537 shares were sold by Ajer Jeffrey Robert, worth $122,484. $318,750 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by LAWLIS V BRYAN on Tuesday, April 17. On Monday, April 23 the insider SPIEGELMAN DANIEL K sold $908,497. HERON ELAINE J also sold $71,116 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares.

The stock of Biomarin Pharmaceutical Inc (NASDAQ:BMRN) registered a decrease of 0.51% in short interest. BMRN’s total short interest was 12.12M shares in May as published by FINRA. Its down 0.51% from 12.18M shares, reported previously. With 1.33 million shares average volume, it will take short sellers 9 days to cover their BMRN’s short positions. The short interest to Biomarin Pharmaceutical Inc’s float is 6.94%.

The stock decreased 1.22% or $1.09 during the last trading session, reaching $88.43. About 715,347 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since May 18, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.63 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 13 analysts covering Biomarin Pharmaceutical (NASDAQ:BMRN), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Biomarin Pharmaceutical had 19 analyst reports since December 14, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Monday, April 30 by Bernstein. As per Monday, May 7, the company rating was maintained by Leerink Swann. JP Morgan maintained it with “Outperform” rating and $129 target in Wednesday, January 24 report. The firm has “Outperform” rating by BMO Capital Markets given on Friday, February 23. The rating was upgraded by Wedbush to “Outperform” on Thursday, December 14. Morgan Stanley maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, April 30 with “Overweight” rating. The firm has “Buy” rating by Stifel Nicolaus given on Friday, February 23. As per Friday, February 23, the company rating was maintained by Leerink Swann. RBC Capital Markets maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, February 27 with “Hold” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Overweight” rating by Morgan Stanley on Friday, February 23.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: which released: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” on May 17, 2018, also with their article: “Premarket analyst action – healthcare” published on May 16, 2018, published: “Sangamo Therapeutics Stock History” on May 17, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: and their article: “BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress” published on May 17, 2018 as well as‘s news article titled: “Andreas Halvorsen Buys Alibaba, United States Steel in 1st Quarter” with publication date: May 15, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: